Potential drug-drug interactions in adults receiving oral anticoagulant and antiaggregant therapy

Background: Anticoagulant and antiaggregant drugs are drug groups with high mortality and the most common cause of malpractice. Research design and Methods: 18 and 65 years were scheduled for pharmacotherapy in the Family Health Center. 122 patients during their anticoagulant and/or antiaggregant treatment were evaluated in terms of drug-drug interactions. Results: Drug-drug interactions were detected in 89.7% of the patients included in the study. A total of 212 drug-drug interactions were found in 122 patients. Of these, 12 (5.6%) were identified as A, 16 (7.5%) B, 146 (68.6%) C, 32 (15.2%) D and 6 (2.8%) X risk category. The number of DDI was found to be significantly higher in patients aged between 56 and 65 years. The most drug interactions are significantly higher in the C and D categories, respectively. The most predicted clinical outcomes of DDI’s were increased in the therapeutic effect and adverse/toxic reactions. Conclusions: Contrary to expectations, it is seen that although polypharmacy is relatively less in patients aged 18–65 years compared to patients over 65 years of age, it is very important to detect drug interactions in this age group in terms of safety, efficacy and treatment benefit in terms of drug-drug interaction.